Biochemical properties and biological functions of FET proteins

Annual Review of Biochemistry

Volumn 84, Issue , 2015, Pages 355-379

  Schwartz, Jacob C ^a   Cech, Thomas R ^a   Parker, Roy R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

EWSR1; FUS; Low complexity; Neurodegeneration; RNA binding; TAF15

Indexed keywords

CELL PROTEIN; DOUBLE STRANDED DNA; FET PROTEIN; FUSED IN SARCOMA PROTEIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; PROTEIN; PROTEIN SM; RNA BINDING PROTEIN EWS; RNA POLYMERASE II; SINGLE STRANDED DNA; TATA BINDING PROTEIN; TATA BOX BINDING PROTEIN 15; UNCLASSIFIED DRUG; RNA BINDING PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR;

AMINO ACID SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CHROMOSOME REARRANGEMENT; CIRCULAR DICHROISM; DEGENERATIVE DISEASE; DNA BINDING; DNA DAMAGE; HUMAN; IMMUNOFLUORESCENCE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RNA BINDING; RNA PROCESSING; RNA SEQUENCE; ACTIVE TRANSPORT; ANIMAL; CHEMISTRY; DNA REPAIR; GENETIC TRANSCRIPTION; METABOLISM; NEOPLASM;

METAZOA;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; DNA REPAIR; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA-BINDING PROTEIN FUS; RNA-BINDING PROTEINS; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TRANSCRIPTION, GENETIC;

EID: 84930705294     PISSN: 00664154     EISSN: 15454509     Source Type: Book Series    
DOI: 10.1146/annurev-biochem-060614-034325     Document Type: Review

References (151)

1. Eberle AB, Visa N. 2014. Quality control of mRNP biogenesis: networking at the transcription site. Semin. Cell Dev. Biol. 32C:37-46
2. Saguez C, Olesen JR, Jensen TH. 2005. Formation of export-competent mRNP: escaping nuclear destruction. Curr. Opin. Cell Biol. 17:287-93
3. Moore MJ, Proudfoot NJ. 2009. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136:688-700
4. Hilleren P, Parker R. 1999. Mechanisms of mRNA surveillance in eukaryotes. Annu. Rev. Genet. 33:229-60
5. Mitchell SF, Parker R. 2014. Principles and properties of eukaryotic mRNPs. Mol. Cell 54:547-58
6. Müller-McNicoll M, Neugebauer KM. 2013. How cells get the message: dynamic assembly and function of mRNA-protein complexes. Nat. Rev. Genet. 14:275-87
7. Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, et al. 2012. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 149:1393-406
8. Piñol-Roma S, Dreyfuss G. 1992. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355:730-32
9. Piñol-Roma S, Dreyfuss G. 1993. hnRNP proteins: localization and transport between the nucleus and the cytoplasm. Trends Cell Biol. 3:151-55
10. Lau JS, Baumeister P, Kim E, Roy B, Hsieh TY, et al. 2000. Heterogeneous nuclear ribonucleoproteins as regulators of gene expression through interactions with the human thymidine kinase promoter. J. Cell Biochem. 79:395-406
11. Tomonaga T, Levens D. 1995. Heterogeneous nuclear ribonucleoprotein K is a DNA-binding transactivator. J. Biol. Chem. 270:4875-81
12. Miau LH, Chang CJ, Shen BJ, Tsai WH, Lee SC. 1998. Identification of heterogeneous nuclear ribonucleoprotein K (hnRNP K) as a repressor of C/EBPβ-mediated gene activation. J. Biol. Chem. 273:10784-91
13. Riggi N, Cironi L, Suva ML, Stamenkovic I. 2007. Sarcomas: genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J. Pathol. 213:4-20
14. Tan AY, Manley JL. 2009. The TET family of proteins: functions and roles in disease. J. Mol. Cell Biol. 1:82-92
15. Han TW, Kato M, Xie S, Wu LC, Mirzaei H, et al. 2012. Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies. Cell 149:768-79
16. Kato M, Han TW, Xie S, Shi K, Du X, et al. 2012. Cell-free formation ofRNAgranules: Low complexity sequence domains form dynamic fibers within hydrogels. Cell 149:753-67
17. Kwon I, Kato M, Xiang S, Wu L, Theodoropoulos P, et al. 2013. Phosphorylation-regulated binding of RNA polymerase II to fibrous polymers of low-complexity domains. Cell 155:1049-60
18. Schwartz JC, Wang X, Podell ER, Cech TR. 2013. RNA seeds higher-order assembly of FUS protein. Cell Rep. 5:918-25
19. KovarH. 2011. Dr. Jekyll and Mr.Hyde: the two faces of the FUS/EWS/TAF15 protein family. Sarcoma 2011:837474
20. Lagier-Tourenne C, Cleveland DW. 2009. Rethinking ALS: the FUS about TDP-43. Cell 136:1001-4
21. Mackenzie IR, Rademakers R, Neumann M. 2010. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9:995-1007
22. Bertolotti A, Lutz Y, Heard DJ, Chambon P, Tora L. 1996. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 15:5022-31
23. Liu X, Niu C, Ren J, Zhang J, Xie X, et al. 2013. The RRM domain of human fused in sarcoma protein reveals a non-canonical nucleic acid binding site. Biochim. Biophys. Acta 1832:375-85
24. Xu RM, Jokhan L, Cheng X, Mayeda A, Krainer AR. 1997. Crystal structure of human UP1, the domain of hnRNP A1 that contains two RNA-recognition motifs. Structure 5:559-70
25. Ding J, Hayashi MK, Zhang Y, Manche L, Krainer AR, Xu RM. 1999. Crystal structure of the two-RRM domain of hnRNP A1 (UP1) complexed with single-stranded telomeric DNA. Genes Dev. 13:1102-15
26. Iko Y, Kodama TS, Kasai N, Oyama T, Morita EH, et al. 2004. Domain architectures and characterization of an RNA-binding protein, TLS. J. Biol. Chem. 279:44834-40
27. Shamoo Y, Krueger U, Rice LM, Williams KR, Steitz TA. 1997. Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75A° resolution. Nat. Struct. Biol. 4:215-22
28. Reijns MA, Alexander RD, Spiller MP, Beggs JD. 2008. A role for Q/N-rich aggregation-prone regions in P-body localization. J. Cell Sci. 121:2463-72
29. Decker CJ, Teixeira D, Parker R. 2007. Edc3p and a glutamine/asparagine-rich domain of Lsm4p function in processing body assembly in Saccharomyces cerevisiae. J. Cell Biol. 179:437-49
30. Gilks N, Kedersha N, Ayodele M, Shen L, Stoecklin G, et al. 2004. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol. Biol. Cell 15:5383-98
31. King OD, Gitler AD, Shorter J. 2012. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462:61-80
32. Calvio C, Neubauer G, Mann M, Lamond AI. 1995. Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry. RNA 1:724-33
33. Takahama K, Kino K, Arai S, Kurokawa R, Oyoshi T. 2011. Identification of Ewing's sarcoma protein (EWS) as a G-quadruplex DNA- and RNA-binding protein. FEBS J. 278:988-98
34. Tan AY, Riley TR, Coady T, Bussemaker HJ, Manley JL. 2012. TLS/FUS (translocated in liposarcoma/ fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. PNAS 109:6040-35
35. Hackl W, Lührmann R. 1996. Molecular cloning and subcellular localisation of the snRNP-associated protein 69KD, a structural homologue of the proto-oncoproteins TLS and EWS with RNA- and DNAbinding properties. J. Mol. Biol. 264:843-51
36. Alliegro MC, Alliegro MA. 1996. A nuclear protein regulated during the transition from active to quiescent phenotype in cultured endothelial cells. Dev. Biol. 174:288-97
37. Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. 2012. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev. 26:2690-95
38. Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. 1997. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 110:1741-50
39. Perrotti D, Iervolino A, Cesi V, Cirinna M, Lombardini S, et al. 2000. BCR-ABL prevents c-Junmediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CβII-dependent pathway. Mol. Cell. Biol. 20:6159-69
40. Gardiner M, Toth R, Vandermoere F, Morrice NA, Rouse J. 2008. Identification and characterization of FUS/TLS as a new target of ATM. Biochem. J. 415:297-307
41. Guipaud O, Guillonneau F, Labas V, Praseuth D, Rossier J, et al. 2006. An in vitro enzymatic assay coupled to proteomics analysis reveals a new DNA processing activity for Ewing sarcoma and TAF(II)68 proteins. Proteomics 6:5962-72
42. Bertrand P, Akhmedov AT, Delacote F, Durrbach A, Lopez BS. 1999. Human POMp75 is identified as the pro-oncoprotein TLS/FUS: Both POMp75 and POMp100 DNA homologous pairing activities are associated to cell proliferation. Oncogene 18:4515-21
43. Baechtold H, Kuroda M, Sok J, Ron D, Lopez BS, Akhmedov AT. 1999. Human 75-kDa DNA-pairing protein is identical to the pro-oncoprotein TLS/FUS and is able to promote D-loop formation. J. Biol. Chem. 274:34337-42
44. Crozat A, Aman P, Mandahl N, Ron D. 1993. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 363:640-44
45. Zinszner H, Albalat R, Ron D. 1994. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 8:2513-26
46. Immanuel D, Zinszner H, Ron D. 1995. Association of SARFH (sarcoma-associated RNA-binding fly homolog) with regions of chromatin transcribed by RNA polymerase II. Mol. Cell. Biol. 15:4562-71
47. Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L. 1998. EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol. Cell. Biol. 18:1489-97
48. Ohno T, Ouchida M, Lee L, Gatalica Z, Rao VN, Reddy ES. 1994. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 9:3087-97
49. Ichikawa H, Shimizu K, Hayashi Y, Ohki M. 1994. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res. 54:2865-68
50. Lerga A, Hallier M, Delva L, Orvain C, Gallais I, et al. 2001. Identification of an RNA binding specificity for the potential splicing factor TLS. J. Biol. Chem. 276:6807-16
51. Hoell JI, Larsson E, Runge S, Nusbaum JD, Duggimpudi S, et al. 2011. RNA targets of wild-type and mutant FET family proteins. Nat. Struct. Mol. Biol. 18:1428-31
52. Yamazaki T, Chen S, Yu Y, Yan B, Haertlein TC, et al. 2012. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA. Cell Rep. 2:799-806
53. Wang X, Arai S, Song X, Reichart D, Du K, et al. 2008. Induced ncRNAs allosterically modify RNAbinding proteins in cis to inhibit transcription. Nature 454:126-30
54. Colombrita C, Onesto E, Megiorni F, Pizzuti A, Baralle FE, et al. 2012. TDP-43 and FUS RNAbinding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their posttranscriptional fate in motoneuron-like cells. J. Biol. Chem. 287:15636-47
55. Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, et al. 2012. Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. Sci. Rep. 2:529
56. Daigle JG, Lanson NA Jr, Smith RB, Casci I, Maltare A, et al. 2013. RNA-binding ability of FUSregulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum. Mol. Genet. 22:1193-205
57. Rogelj B, Easton LE, Bogu GK, Stanton LW, Rot G, et al. 2012. Widespread binding of FUS along nascent RNA regulates alternative splicing in the brain. Sci. Rep. 2:603
58. Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, et al. 2012. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15:1488-97
59. Takahama K, Oyoshi T. 2013. Specific binding of modified RGGdomain in TLS/FUS toG-quadruplex RNA: Tyrosines inRGGdomain recognize 2′-OH of the riboses of loops in G-quadruplex. J. Am. Chem. Soc. 135:18016-19
60. Ray D, Kazan H, Cook KB, Weirauch MT, Najafabadi HS, et al. 2013. A compendium of RNA-binding motifs for decoding gene regulation. Nature 499:172-77
61. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, et al. 2011. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLOS Biol. 9:e1000614
62. Doi H, Okamura K, Bauer PO, Furukawa Y, Shimizu H, et al. 2008. RNA-binding proteinTLS is amajor nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J. Biol. Chem. 283:6489-500
63. Shaw DJ, Morse R, Todd AG, Eggleton P, Lorson CL, Young PJ. 2010. Identification of a self-association domain in the Ewing's sarcoma protein: a novel function for arginine-glycine-glycine rich motifs? J. Biochem. 147:885-93
64. Vance C, Scotter EL, Nishimura AL, Troakes C, Mitchell JC, et al. 2013. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 22:2676-88
65. Yamaguchi A, Kitajo K. 2012. The effect of PRMT1-mediated arginine methylation on the subcellular localization, stress granules, and detergent-insoluble aggregates of FUS/TLS. PLOS ONE 7:e49267
66. Mackenzie IR, Munoz DG, Kusaka H, Yokota O, Ishihara K, et al. 2011. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 121:207-18
67. Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, et al. 2010. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum. Mol. Genet. 19:4160-75
68. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, et al. 2009. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:1208-11
69. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, et al. 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:1205-8
70. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, et al. 2011. A yeast model of FUS/TLS-dependent cytotoxicity. PLOS Biol. 9:e1001052
71. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, et al. 2012. A travel guide to Cytoscape plugins. Nat. Methods 9:1069-76
72. Ballarino M, Jobert L, Dembele D, de la Grange P, Auboeuf D, Tora L. 2013. TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs. Oncogene 32:4646-55
73. Morlando M, Dini Modigliani S, Torrelli G, Rosa A, Di Carlo V, et al. 2012. FUS stimulates microRNA biogenesis by facilitating co-transcriptional Drosha recruitment. EMBO J. 31:4502-10
74. Thomsen C, Grundevik P, Elias P, Stahlberg A, Aman P. 2013. A conserved N-terminal motif is required for complex formation between FUS, EWSR1, TAF15 and their oncogenic fusion proteins. FASEB J. 27:4965-74
75. Korennykh AV, Egea PF, Korostelev AA, Finer-Moore J, Zhang C, et al. 2009. The unfolded protein response signals through high-order assembly of Ire1. Nature 457:687-93
76. Lyumkis D, Talley H, Stewart A, Shah S, Park CK, et al. 2013. Allosteric regulation of DNA cleavage and sequence-specificity through run-on oligomerization. Structure 21:1848-58
77. Araya N, Hirota K, Shimamoto Y, Miyagishi M, Yoshida E, et al. 2003. Cooperative interaction of EWS with CREB-binding protein selectively activates hepatocyte nuclear factor 4-mediated transcription. J. Biol. Chem. 278:5427-32
78. Lee J, Rhee BK, Bae GY, Han YM, Kim J. 2005. Stimulation of Oct-4 activity by Ewing's sarcoma protein. Stem Cells 23:738-51
79. Tan AY, Manley JL. 2010. TLS inhibits RNA polymerase III transcription. Mol. Cell. Biol. 30:186-96
80. Yang L, Embree LJ, Hickstein DD. 2000. TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol. Cell. Biol. 20:3345-54
81. Chansky HA, Hu M, Hickstein DD, Yang L. 2001. Oncogenic TLS/ERG and EWS/FLI-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res. 61:3586-90
82. Das R, Yu J, Zhang Z, Gygi MP, Krainer AR, et al. 2007. SR proteins function in coupling RNAP II transcription to pre-mRNA splicing. Mol. Cell 26:867-81
83. Rabbitts TH, Forster A, Larson R, Nathan P. 1993. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat. Genet. 4:175-80
84. Panagopoulos I, Aman P, Fioretos T, Hoglund M, Johansson B, et al. 1994. Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 11:256-62
85. Law WJ, Cann KL, Hicks GG. 2006. TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct. Genomics Proteomics 5:8-14
86. Zhang D, Paley AJ, Childs G. 1998. The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J. Biol. Chem. 273:18086-91
87. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. 1993. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13:7393-98
88. Bertolotti A, Bell B, Tora L. 1999. The N-terminal domain of human TAFII68 displays transactivation and oncogenic properties. Oncogene 18:8000-10
89. Hancock JD, Lessnick SL. 2008. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 7:250-56
90. Zou J, Ichikawa H, Blackburn ML, Hu HM, Zielinska-Kwiatkowska A, et al. 2005. The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts. Mol. Cell. Biol. 25:6235-46
91. Kuroda M, Sok J, Webb L, Baechtold H, Urano F, et al. 2000. Male sterility and enhanced radiation sensitivity in TLS-/-mice. EMBO J. 19:453-62
92. Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH. 1998. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol. Endocrinol. 12:4-18
93. Perrotti D, Bonatti S, Trotta R, Martinez R, Skorski T, et al. 1998. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J. 17:4442-55
94. Deloulme JC, Prichard L, Delattre O, Storm DR. 1997. The prooncoprotein EWS binds calmodulin and is phosphorylated by protein kinase C through an IQ domain. J. Biol. Chem. 272:27369-77
95. Bachmaier R, Aryee DN, Jug G, Kauer M, Kreppel M, et al. 2009. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma. Oncogene 28:1280-84
96. Jobert L, Argentini M, Tora L. 2009. PRMT1mediated methylation ofTAF15 is required for its positive gene regulatory function. Exp. Cell Res. 315:1273-86
97. Araya N, Hiraga H, Kako K, Arao Y, Kato S, Fukamizu A. 2005. Transcriptional down-regulation through nuclear exclusion of EWS methylated by PRMT1. Biochem. Biophys. Res. Commun. 329:653-60
98. Belyanskaya LL, Delattre O, Gehring H. 2003. Expression and subcellular localization of Ewing sarcoma (EWS) protein is affected by the methylation process. Exp. Cell Res. 288:374-81
99. Yang L, Chansky HA, Hickstein DD. 2000. EWS.Fli1 fusion protein interactswith hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J. Biol. Chem. 275:37612-18
100. Hallier M, Lerga A, Barnache S, Tavitian A, Moreau-Gachelin F. 1998. The transcription factor Spi- 1/PU.1 interacts with the potential splicing factor TLS. J. Biol. Chem. 273:4838-42
101. Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, et al. 2001. Involvement of the prooncoprotein TLS (translocated in liposarcoma) in nuclear factor κB p65-mediated transcription as a coactivator. J. Biol. Chem. 276:13395-401
102. Pérez-Losada J, Sánchez-Martín M, Rodríguez-García MA, Pérez-Mancera PA, Pintado B, et al. 2000. Liposarcoma initiated by FUS/TLS-CHOP: The FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 19:6015-22
103. Ichikawa H, Shimizu K, Katsu R, Ohki M. 1999. Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS). Mol. Cell. Biol. 19:7639-50
104. Prasad DD, Ouchida M, Lee L, Rao VN, Reddy ES. 1994. TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain. Oncogene 9:3717-29
105. Martini A, La Starza R, Janssen H, Bilhou-Nabera C, Corveleyn A, et al. 2002. Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia. Cancer Res. 62:5408-12
106. Kuroda M, Wang X, Sok J, Yin Y, Chung P, et al. 1999. Induction of a secreted protein by the myxoid liposarcoma oncogene. PNAS 96:5025-30
107. Braun BS, Frieden R, Lessnick SL, May WA, Denny CT. 1995. Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis. Mol. Cell. Biol. 15:4623-30
108. Paronetto MP, Minana B, Valcarcel J. 2011. TheEwing sarcoma protein regulatesDNA damage-induced alternative splicing. Mol. Cell 43:353-68
109. Meissner M, Lopato S, Gotzmann J, Sauermann G, Barta A. 2003. Proto-oncoprotein TLS/FUS is associated to the nuclear matrix and complexed with splicing factors PTB, SRM160, and SR proteins. Exp. Cell Res. 283:184-95
110. Muñoz MJ, Pérez-Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, et al. 2009. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 137:708-20
111. Leichter M, Marko M, Ganou V, Patrinou-Georgoula M, Tora L, Guialis A. 2011. A fraction of the transcription factor TAF15 participates in interactions with a subset of the spliceosomal U1 snRNP complex. Biochim. Biophys. Acta 1814:1812-24
112. de Hoog CL, Foster LJ, Mann M. 2004. RNA and RNA binding proteins participate in early stages of cell spreading through spreading initiation centers. Cell 117:649-62
113. Bres V, Yoh SM, Jones KA. 2008. The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 20:334-40
114. Todd AG, Morse R, Shaw DJ, Stebbings H, Young PJ. 2010. Analysis of SMN-neurite granules: Core Cajal body components are absent from SMN-cytoplasmic complexes. Biochem. Biophys. Res. Commun. 397:479-85
115. Tsuiji H, Iguchi Y, Furuya A, Kataoka A, Hatsuta H, et al. 2013. Spliceosome integrity is defective in the motor neuron diseases ALS and SMA. EMBO Mol. Med. 5:221-34
116. Mackenzie IR, Neumann M. 2012. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res. 1462:40-43
117. Neumann M, Bentmann E, Dormann D, Jawaid A, DeJesus-Hernandez M, et al. 2011. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134:2595-609
118. Leemann-Zakaryan RP, Pahlich S, Grossenbacher D, Gehring H. 2011. Tyrosine phosphorylation in the C-terminal nuclear localization and retention signal (C-NLS) of the EWSprotein. Sarcoma 2011:218483
119. Zhang ZC, Chook YM. 2012. Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS). PNAS 109:12017-21
120. Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, et al. 2012. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 31:4258-75
121. Scaramuzzino C, Monaghan J, Milioto C, Lanson NA Jr, Maltare A, et al. 2013. Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo. PLOS ONE 8:e61576
122. Tradewell ML, Yu Z, Tibshirani M, Boulanger MC, Durham HD, Richard S. 2012. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum. Mol. Genet. 21:136-49
123. Belyanskaya LL, Gehrig PM, Gehring H. 2001. Exposure on cell surface and extensive arginine methylation of Ewing sarcoma (EWS) protein. J. Biol. Chem. 276:18681-87
124. Fujii R, Grossenbacher-Zinchuk O, Jamari I, Wang Y, Zinchuk V, Takumi T. 2009. TLS-GFP cannot rescue mRNP formation near spines and spine phenotype in TLS-KO. Neuroreport 20:57-61
125. Fujii R, Takumi T. 2005. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J. Cell Sci. 118:5755-65
126. Fujii R, Okabe S, Urushido T, Inoue K, Yoshimura A, et al. 2005. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr. Biol. 15:587-93
127. Andersson MK, Stahlberg A, Arvidsson Y, Olofsson A, Semb H, et al. 2008. The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. BMC Cell Biol. 9:37
128. Yasuda K, Zhang H, Loiselle D, Haystead T, Macara IG, Mili S. 2013. The RNA-binding protein Fus directs translation of localized mRNAs in APC-RNP granules. J. Cell Biol. 203:737-46
129. Sama RR, Ward CL, Kaushansky LJ, Lemay N, Ishigaki S, et al. 2013. FUS/TLS assembles into stress granules and is a prosurvival factor during hyperosmolar stress. J. Cell Physiol. 228:2222-31
130. Li YR, King OD, Shorter J, Gitler AD. 2013. Stress granules as crucibles of ALS pathogenesis. J. Cell Biol. 201:361-72
131. Ramaswami M, Taylor JP, Parker R. 2013. Altered ribostasis: RNA-protein granules in degenerative disorders. Cell 154:727-36
132. Blokhuis AM, Groen EJ, Koppers M, van den Berg LH, Pasterkamp RJ. 2013. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 125:777-94
133. Polymenidou M, Lagier-Tourenne C, Hutt KR, Bennett CF, Cleveland DW, Yeo GW. 2012. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain Res. 1462:3-15
134. Ibrahim F, Nakaya T, Mourelatos Z. 2012. RNA dysregulation in diseases of motor neurons. Annu. Rev. Pathol. Mech. Dis. 7:323-52
135. Ticozzi N, Vance C, Leclerc AL, Keagle P, Glass JD, et al. 2011. Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med. Genet. B 156:285-90
136. Shelkovnikova TA, Robinson HK, Southcombe JA, Ninkina N, Buchman VL. 2014. Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Hum. Mol. Genet. 23:2511-26
137. Baron DM, Kaushansky LJ, Ward CL, Sama RR, Chian RJ, et al. 2013. Amyotrophic lateral sclerosis-linked FUS/TLS alters stress granule assembly and dynamics. Mol. Neurodegener. 8:30
138. Deng H, Gao K, Jankovic J. 2014. The role of FUS gene variants in neurodegenerative diseases. Nat. Rev. Neurol. 10:337-48
139. Ticozzi N, Silani V, LeClerc AL, Keagle P, Gellera C, et al. 2009. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology 73:1180-85
140. Ito D, Seki M, Tsunoda Y, Uchiyama H, Suzuki N. 2010. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann. Neurol. 69:152-62
141. Schwartz JC, Podell ER, Han SSW, Berry JD, Eggan KC, Cech TR. 2014. FUS is sequestered in nuclear aggregates in ALS patient fibroblasts. Mol. Biol. Cell. 25:2571-78
142. Kabashi E, Bercier V, Lissouba A, Liao M, Brustein E, et al. 2011. FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLOS Genet. 7:e1002214
143. Qiu H, Lee S, Shang Y, Wang WY, Au KF, et al. 2014. ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J. Clin. Investig. 124:981-99
144. Wang WY, Pan L, Su SC, Quinn EJ, Sasaki M, et al. 2013. Interaction of FUS and HDAC1 regulates DNA damage response and repair in neurons. Nat. Neurosci. 16:1383-91
145. Mastrocola AS, Kim SH, Trinh AT, Rodenkirch LA, Tibbetts RS. 2013. The RNA-binding protein fused in sarcoma (FUS) functions downstream of poly(ADP-ribose) polymerase (PARP) in response to DNA damage. J. Biol. Chem. 288:24731-41
146. Lee HJ, Yoon C, Schmidt B, Park DJ, Zhang AY, et al. 2013. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol. Cancer Ther. 12:2591-600
147. Li H, Watford W, Li C, Parmelee A, Bryant MA, et al. 2007. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J. Clin. Investig. 117:1314-23
148. Hicks GG, Singh N, Nashabi A, Mai S, Bozek G, et al. 2000. Fus deficiency in mice results in defective B-lymphocyte development and activation, high levels of chromosomal instability and perinatal death. Nat. Genet. 24:175-79
149. Sugawara T, Oguro H, Negishi M, Morita Y, Ichikawa H, et al. 2010. FET family proto-oncogene Fus contributes to self-renewal of hematopoietic stem cells. Exp. Hematol. 38:696-706
150. Brenner JC, Feng FY, Han S, Patel S, Goyal SV, et al. 2012. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72:1608-13
151. Yoshida K. 2008. Nuclear trafficking of pro-apoptotic kinases in response to DNA damage. Trends Mol. Med. 14:305-13